Drupal.behaviors.print = function(context) {window.print();window.close();}>
Arrowhead to Move Calando Cancer Drug into Phase Ib, Reports Fiscal Q3 Results
August 11, 2011
Arrowhead to Move Calando Cancer Drug into Phase Ib, Reports Fiscal Q3 Results
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Arrowhead Names HBV as Next RNAi Program While It Consolidates Operations
February 16, 2012 / Gene Silencing News
Arrowhead Preps Phase I siRNA Drug Data for Publication, Raises $3.2M in Private Placement
December 31, 2009 / Gene Silencing News
Arrowhead Offers Timeline for HBV Candidate, Plans Two Phase I Trials
February 14, 2013 / Gene Silencing News
Arrowhead Promises RNAi Deal, Phase I in 2013 as Investors Voice Worries
August 16, 2012 / Gene Silencing News
Alnylam Shares Still Flying on ATTR Results, But Not All RNAi Drug Firms Get as Big a Boost on Data
August 2, 2012 / Gene Silencing News